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Abstract: Biologic agents, including targeted antibodies as well as immunomodulators, are demonstrating
unparalleled development and study across the entire spectrum of human malignancy. This review
summarizes the current state of biologic therapies for esophageal, esophagogastric, and gastric malignancies,
including those that target human epidermal growth factor receptor 2 (HER2), epidermal growth factor
receptor (EGFR), vascular endothelial growth factor (VEGF), c-Met, mechanistic target of rapamycin
(mTOR) and immunomodulators. We focus primarily on agents that have been included in phase II and
III clinical trials in locally advanced, progressive, or metastatic esophageal and gastric malignancies. At
this time, only two biologic therapies are recommended by the National Comprehensive Cancer Network
(NCCN): trastuzumab for patients with esophageal/esophagogastric or gastric adenocarcinomas with
HER2 overexpression and ramucirumab, a VEGFR-2 inhibitor, as a second-line therapy for metastatic
disease. However, recent reports of increases in overall and progression-free survival for agents including
pertuzumab, apatinib, and pembrolizumab will likely increase the use of targeted biologic therapy in clinical
practice for esophageal and gastric malignancies.
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Introduction
Esophageal and gastric cancers continue to pose a
significant burden of morbidity and mortality globally. In
2012, it was estimated that gastric cancer was the fifth most
common cancer worldwide, and the third leading cause
of cancer death (1). Esophageal cancer, while incidentally
less common than gastric cancer, has a striking mortality
rate, placing it as the sixth leading cause of cancer related
deaths worldwide (1). Furthermore, it has been known
for the past few decades that the incidence of esophageal
adenocarcinoma has substantially increased, mirroring the
prevalence of gastroesophageal reflux disease and Barrett’s
esophagus, particularly in North American and Europe (2,3).
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While important advances have been made in the early
detection and treatment of esophageal and gastric cancers,
the majority of patients continue to present with clinical
evidence of regional or distant disease (4). While treatment
for esophageal and gastric cancers has traditionally
involved combinations of aggressive surgical resection,
chemotherapy, and radiotherapy, the percent of patients
achieving 5-year survival remains under 20% (4). Because of
the intractable nature of these diseases, it is not surprising
that attention has turned towards biologic therapies to offer
a more tailored, and potentially effective, treatment option.
This review will examine biologic therapies that now have
established efficacy in esophageal and gastric cancers, as
well as those that are currently under investigation and hold
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Table 1 Potential biologic targets in esophageal, esophagogastric, and gastric malignancies, and the agents that have been evaluated to date
Biologic target

Targeted agents evaluated for esophageal, EGJ, and gastric malignancies

HER-2

Trastuzumab approved in 1st-line;
Negative studies with lapatinib and T-DM1 (trastuzumab emtansine) in 2nd-line;
Pertuzumab remains under investigation (JACOB trial, TRAP trial)

EGFR

Multiple negative studies with cetuximab and panitumumab in a variety of clinical settings

VEGF and VEGFR

Ramucirumab approved in 2nd-line;
Negative 1st-line studies with ramucirumab, ziv-aflibercept and bevacizumab;
Positive phase III study of apatinib in the refractory setting

c-MET

Negative 1st-line studies with foretinib, onartuzumab, and rilotumumab

mTOR

Negative 2nd-line study with everolimus

PD-1

Pembrolizumab and nivolumab with promising phase I/II trials, need to be evaluated with phase III study

potential benefit (Table 1).
Human epidermal growth factor receptor 2
(HER2) targeted therapies
Initially discovered as an overexpressed transmembrane
tyrosine kinase receptor in approximately one-third of
breast cancer patients that was associated with decreased
survival, HER2, or c-erb-2, proto-oncogene quickly became
an important tumor marker and target for therapy (5).
Given the fact that HER2 is constitutively expressed on
many different epithelial cell types, studies sought to
understand its prevalence in other malignancies, including
esophageal and gastric cancers (6). It is estimated that
approximately 30% of gastroesophageal adenocarcinomas
and 20% of gastric cancers overexpress HER2, and early
studies showed wide variability of overexpression depending
on the specific method of testing (7,8). Rates for HER2
overexpression in squamous cell carcinoma of the esophagus
has been found to range from 5% to almost 40% (9,10).
Once HER2 was found to be overexpressed in subgroups
of esophageal, esophagogastric, and gastric cancer patients,
the next question was whether this oncogene was associated
with poorer survival rates as seen in breast cancer. Early
institutional studies evaluating HER2 overexpression and
long-term overall survival were known for conflicting
findings (11,12). In a meta-analysis of operable esophageal
cancer patients, it was found that among high-quality
analyses, esophageal adenocarcinoma patients with
overexpression of HER2 [most commonly defined in early
reports as immunohistochemistry (IHC), ≥2] had poorer
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5-year all-cause mortality (OR 1.9; 95% CI, 1.2–3.2;
P=0.001) (13). This increased rate of 5-year mortality was
also detected for squamous cell esophageal carcinoma (OR
2.9; 95% CI, 1.3–6.2; P=0.006) (13). For gastric cancers,
previous work has demonstrated that HER2 overexpression
ranges from 8–20% (with slightly higher rates for HER3
and HER4), although correlation between expression
of the HER2 subtypes has been demonstrated (14,15).
Amplification in gastric cancer has been found to be
strongly associated with intestinal type adenocarcinoma
and significantly reduced overall survival (14,15). Current
NCCN guidelines recommend that patients with inoperable
locally advanced, recurrent, or metastatic adenocarcinomas
of the esophagus, esophagogastric junction, or stomach be
considered for tailored therapy in cases of 3+ overexpression
by IHC or fluorescence in situ hybridization (FISH)
positive (HER2:CEP17 ratio ≥2), and patients that are 2+
be additionally examined by FISH (16).
Trastuzumab
After the emergence of trastuzumab as a standard of care
for breast cancer patients with HER2 overexpression due
to successes in improving overall survival among those with
metastatic disease, there was great interest to evaluate its use
among other tumor sites (17). Trastuzumab is a monoclonal
antibody specific for HER2 that prevents activation of the
intracellular kinase activity, with described mechanisms
including prevention of HER2 receptor dimerization,
endocytic destruction of the receptor, decreased shedding
of the extracellular domain, and increased cell-mediated
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cytotoxicity (18).
From 2005 to 2009, the Trastuzumab for Gastric Cancer
(ToGA) randomized controlled trial evaluated the safety and
clinical efficacy of this agent for locally advanced, recurrent
or metastatic adenocarcinoma of the gastroesophageal
junction or stomach (19). For study entry, patients’ tumors
were considered to overexpress HER2 if they were scored as
3+ on IHC or were FISH positive (HER2/CEP17 ratio >2).
All patients received chemotherapy consisting of either
capecitabine plus cisplatin or fluorouracil plus cisplatin
every 3 weeks for six cycles, with those being randomized to
the study treatment also receiving concurrent trastuzumab.
Patients receiving trastuzumab with chemotherapy
did have a significant improvement in median overall
survival compared to the chemotherapy only arm (13.8 vs.
11.1 months), with no difference in grade 3 or 4 adverse
events. On exploratory analyses, this improvement in
overall survival was even more pronounced among patients
with IHC 3+ or IHC 2+ with positive FISH (16.0 vs.
11.8 months). Additionally, patients in the trastuzumab
and chemotherapy arm experienced longer progressionfree survival (6.7 vs. 5.5 months) and higher rates of overall
tumor response (47% vs. 35%). This trial established
trastuzumab as a standard of care agent for patients with
esophagogastric/gastric adenocarcinoma with HER2
overexpression.
A modification to enhance the effect of HER2 targeted
therapy included the development of trastuzumab
emtansine, an antibody-drug conjugate. Trastuzumab binds
the HER2 receptor as previously described and emtansine
(also called DM1) is internalized and inhibits cell division
by binding to tublin, thereby inhibiting microtubule
polymerization. This agent was evaluated in the GATSBY
randomized controlled trial comparing trastuzumab
emtansine with either paclitaxel or docetaxel versus a taxane
only in patients with locally advanced/metastatic HER2
positive gastric or gastroesophageal cancer that had shown
progression on first line fluoropyrimidine and platinum
therapy (20). Of note, the majority of the approximately
400 patients randomized in this trial had received prior
HER2 targeted therapy (77%). Ultimately, the novel
combination of trastuzumab with emtansine did not result
in improvements in overall survival compared to taxane
therapy (7.9 vs. 8.6 months, P=0.86) or median progressionfree survival (2.7 vs. 2.9 months, P=0.31).
As a substantial proportion of patients receive neoadjuvant
chemoradiation therapy prior to esophagectomy for locally
advanced disease, a logical extension of this neoadjuvant
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approach was to add concurrent trastuzumab to standard
chemoradiation to the neoadjuvant therapy of patients with
HER2 overexpressing tumors. RTOG 1010 is a phase III
trial evaluating the addition of trastuzumab to neoadjuvant
chemoradiation (paclitaxel and carboplatin with 50.4 Gy
at 1.8 Gy/fraction) followed by surgery for esophageal or
esophagogastric adenocarcinoma (21). Following recovery
from esophagectomy, patients will continue to receive
trastuzumab every 3 weeks, for 13 additional doses as
maintenance therapy. Currently this multicenter trial has
met accrual targets and results are pending.
Lapatinib
While patients with HER2 overexpression experienced
a significant survival benefit with trastuzumab, the
search for additional HER2 targets with more durable
effects continued. One such endeavor was the Lapatinib
Optimization Study in HER2-Positive Gastric Cancer
(LOGiC) trial, a phase III randomized controlled study to
evaluate clinical response of the first oral tyrosine kinase
inhibitor of both HER2 and epidermal growth factor
receptor (EGFR) in addition to capecitabine and oxaliplatin
in patients with unresectable esophageal, gastroesophageal,
or gastric adenocarcinoma (22). While there was an
improvement in the response rate, no significant difference
was detected in median overall survival. On subgroup
analysis, while there was no difference in the mortality
hazard for the lapatinib arm based on HER2 IHC status,
significant improvements were seen in survival for patients
under 60 years of age and in Asia. Lapatinib was also
evaluated as a second line therapy in addition to weekly
paclitaxel (TyTAN trial) in Asian patients with disease
progression following gastric cancer therapy with HER2
overexpression (23). Again, while response rates were
improved, there was no significant difference found in
progression-free survival or overall survival. These negative
studies have distinguished gastroesophageal cancers from
breast cancers where these approaches yielded improved
outcomes for patients. Additionally, in breast cancer, HER2
treatment is continued beyond tumor progression with firstline therapy; this strategy has not been proven successful in
treating gastroesophageal cancers.
Pertuzumab
Recently, pertuzumab has evolved as another possible
adjunct therapy for HER2 overexpressing malignancies.
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Pertuzumab binds to a different epitope of the HER2
extracellular domain, ultimately preventing dimerization
with other receptors in the HER family, in addition to the
stimulation of cell-mediated cytotoxicity that trastuzumab
was known to cause (24). A randomized controlled trial in
patients with HER2 positive metastatic breast cancer which
compared pertuzumab with trastuzumab to trastuzumab
alone (with both arms receiving docetaxel) found that
patients in the pertuzumab and trastuzumab arm had
significantly longer median progression-free survival with
similar safety profiles (25). Work evaluating pertuzumab
for esophageal and gastric cancer patients is also underway.
A phase IIA trial examining administration of pertuzumab
in addition to trastuzumab, capecitabine, and cisplatin in
patients with locally advanced, inoperable, or metastatic
HER2 positive adenocarcinoma of the gastroesophageal
junction or stomach (JOSHUA) established dosing
parameters and established the safety profile for a phase III
evaluation (JACOB), which is currently ongoing at over
190 study centers (26,27). This agent is additionally being
evaluated in a novel neoadjuvant regimen: the TRAP trial
(Study of Chemoradiation, Trastuzumab, and Pertuzumab
in Resectable HER2+ Esophageal Carcinoma) which is
seeking to establish the feasibility of this multimodality
neoadjuvant regimen and its impact on pathologic response,
surgical margins, and postoperative complications (28).
HER1/EGFR targeted therapies
Gene amplification and overexpression of EGFR (or HER1)
has also been documented in several malignancies including
esophageal, esophagogastric, and gastric tumors. EGFR is a
transmembrane protein that also has tyrosine kinase activity
in the presence of ligands such as epidermal growth factor
and transforming growth factor-α (29). Previous work has
demonstrated that increased EGFR expression (2+ or 3+)
is present in over 30% of esophageal and esophagogastric
adenocarcinomas, and was associated with higher pathologic
T, N, and M stage (30). In esophageal squamous cell cancer,
even higher rates of EGFR overexpression have been
documented, with some studies exceeding 70%, and have
also been correlated with more advanced pathologic stages
and poorer overall survival (31,32).
Cetuximab
Cetuximab, a chimeric monoclonal antibody targeted against
EGFR, had shown efficacy in certain groups of metastatic
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head and neck, colon, and lung cancers and was eventually
tested in patients with esophageal and gastric malignancies
(33-35). The EXPAND trial evaluated cetuximab in the
setting of capecitabine and cisplatin for patients with
locally advanced or metastatic adenocarcinoma of the
gastroesophageal junction or stomach, at over 100 sites in
25 countries (36). Unfortunately, there was no significant
improvement in progression-free survival, and a higher rate
of grade 3–4 adverse events in patients receiving cetuximab
compared to those receiving capecitabine and cisplatin alone.
Panitumumab
The REAL3 phase III trial (epirubicin, oxaliplatin, and
capecitabine with or without panitumumab) which evaluated
an alternate EGFR inhibitor in patients with locally advanced
inoperable or metastatic esophageal cancer (without
molecular testing) actually found an increased mortality
hazard among patients in the panitumumab arm (n=254) (37).
However, questions remained if there may be a benefit
of EGFR inhibitors to select patient populations. For
example, it is known that radiation therapy can increase
EGFR expression in tumors, as well as increase the TGFα
activation of the receptor, so recent phase II and phase III
trials have sought to evaluate the effect of EGFR inhibitors
during concurrent radiation therapy, as a means to improve
local control and response rates (38). However, a phase
II trial of preoperative chemoradiation with concurrent
panitumumab in patients with resectable esophageal cancer
(the PACT study) did not improve the pathologic complete
response (pCR) rate past the pre-defined goal of 40% (39).
Similarly, ACOSOG Z4051, which was a phase II trial
evaluating a neoadjuvant regimen of docetaxel, cisplatin,
panitumumab, and 50.4 Gy in 1.8 Gy/fraction, followed by
esophagectomy, achieved a pCR rate of 33.3%, but did not
reach the primary objective of a pCR rate of ≥35% (40).
Additionally, almost half of patients experienced a toxicity
of ≥4. Given EGFR inhibitors’ lack of efficacy, and evidence
of possible harm in some patient groups, this family of
agents has largely been abandoned for esophageal and
gastric malignancies until improved techniques to select
appropriate patients that may benefit from these agents can
be identified and validated.
Vascular endothelial growth factor (VEGF)
targeted therapies
Similar to other tumor types, the pathways of neoangiogenesis
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have been considered as potential targets in esophageal and
gastric cancer. The VEGF family has long been documented
to regulate tumor angiogenesis and lymphangiogenesis.
However, it has been challenging to determine which specific
tumor profiles may benefit the most from VEGF inhibitors.
While not routinely used in most clinical practices, possible
surrogates of VEGF activity (and potential markers of
response to VEGF inhibitors) have included high tumor
microvessel count (MVC), high proliferating cell nuclear
antigen (PCNA), VEGF:basic fibroblastic growth factor
(bFGF) ratio, as well as VEGF polymorphism subtyping (41).
However, given the fact that activity of the VEGF family
nearly ubiquitously stimulates angiogenesis to promote
tumor growth, survival, and eventually migration, VEGF
inhibitors have been assessed in many tumor types in the
absence of specific tumor marker categorization.
Bevacizumab
One of the agents investigated in this family was
bevacizumab, a VEGF-A inhibitor. The AVAGAST phase
III trial evaluated bevacizumab in combination with cisplatin
and capecitabine (or fluorouracil) for patients with previously
untreated locally advanced or metastatic adenocarcinoma
of the gastroesophageal junction or stomach (42). While
the addition of bevacizumab to first-line chemotherapy did
not result in improvements in overall survival, a significant
improvement in progression-free survival (6.7 vs. 5.3 months)
and overall response rate (46% vs. 37.4%) was detected.
On subgroup analysis, significant decreases in overall
mortality hazard was detected for patients from North or
South America (but not for European or Asian patients)
and for those patients with locally advanced disease (but not
with metastatic disease). A latter study of blood and tissue
markers from patients in the AVAGAST trial demonstrated
that patients with higher baseline levels of VEGF-A
and lower levels of neurophilin-1 (a transmembrane
glycoprotein) were more sensitive to bevacizumab treatment
with significant improvements in overall survival (43). Of
note, this finding still showed geographic variation, with
Asian patients not demonstrating the same benefit with
bevacizumab, despite high VEGF-A levels.
Ramucirumab
Ramucirumab, a VEGFR-2 inhibitor that prevents VEGF
binding in endothelial cells, was assessed as a second
line therapy after platinum or fluoropyrimidine therapy
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for recurrent or metastatic gastroesophageal junction
or gastric cancer (REGARD) (44). In this multicenter
trial, improvements in median overall survival did reach
significance (5.2 months for the ramucirumab arm vs.
3.8 months in the placebo arm), as did the improvement
in median progression free survival (2.1 vs. 1.3 months,
respectively). Ramucirumab was further evaluated with
concurrent paclitaxel in locally advanced or metastatic
esophagogastric or gastric adenocarcinoma with evidence
of disease progression after first line chemotherapy
(platinum and fluoropyrimidine doublet, with or without
anthracycline), in the phase III RAINBOW trial (45).
Compared to the paclitaxel only arm, patients that also
received ramucirumab experienced longer median overall
survival (9.6 vs. 7.4 months). Of note, patients in the
combined ramucirumab and paclitaxel arm did experience
higher rates of selected Grade 3 or higher adverse events
including neutropenia, leucopenia, and hypertension.
However, based on these findings, ramucirumab is now
a preferred second-line therapy for metastatic or locally
advanced esophagogastric or gastric adenocarcinoma
(category 1 recommendation from the NCCN) and
esophageal adenocarcinoma (category 2A) (16). Evaluation
of ramucirumab as a first-line agent to date has not
been endorsed. A multicenter phase II trial evaluating
ramucirumab with leucovorin, fluorouracil, oxaliplatin
(FOLFOX) in patients with previously untreated locally
advanced or metastatic unresectable gastroesophageal or
gastric adenocarcinoma found no difference compared
to FOLFOX with placebo for median progression free
survival (6.4 vs. 6.7 months) or overall survival 11.7 vs.
11.5 months (46). Of note, this trial had a relatively high
proportion of esophageal adenocarcinomas in each arm
(46% in the ramucirumab and FOLFOX group and 49%
in the FOLFOX/placebo group), and was conducted at
centers in the United States only. While the progression
free survival rate was significantly higher at 3 months for
the ramucirumab and FOLFOX patients (89% vs. 75%,
P=0.02), this did not persist at 6, 9, or 12 months. A phase
III randomized trial (RAINFALL) is currently in progress
to assess ramucirumab as a first-line agent with cisplatin
and capecitabine or 5-FU in HER2 negative metastatic
gastroesophageal or gastric adenocarcinoma patients at over
130 centers globally (47).
Apatinib
The most recently assessed VEGF inhibitor for gastric
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malignancy is apatinib, a tyrosine kinase inhibitor that
demonstrates strong affinity and selectivity for VEGFR-2.
A phase II trial of apatinib for advanced or metastatic
esophagogastric or gastric adenocarcinoma refractory to
at least two chemotherapeutic agents (including platinum
and fluoropyrimidine agents) demonstrated improvements
in both median overall survival (4.8 vs. 2.5 months in the
placebo arm) and progression free survival (3.7 vs. 1.4 months
respectively) (48). Based on these promising results from
the phase II study, once daily oral dosing of apatinib (with
a treatment cycle of 28 days) was selected for comparison
to placebo in a multicenter randomized controlled trial at
over 30 centers in China (49). Again, advanced or metastatic
gastric adenocarcinoma patients in the apatinib arm
experienced improved median overall survival compared
to placebo (6.5 vs. 4.7 months) and longer progression free
survival (2.6 vs. 1.8 months, respectively). Apatinib was
generally well tolerated in this trial, with 8.5% experiencing
grade 3 or 4 hand-foot skin reaction, 4.5% grade 3 or 4
hypertension, and 2.3% grade 3 or 4 proteinuria. At this
time, apatinib is not approved for use in the U.S.
c-Met Targeted Therapy
c-Met (mesenchymal-epithelial transition factor) is a
transmembrane tyrosine kinase receptor that is activated
upon binding the hepatocyte growth factor (HGF) with
overexpression being associated with poorer survival in
gastric cancer as well as other malignancies (50). While
c-Met overexpression has been documented with relatively
low rates among gastric malignancies (approximately
10%), this value is remarkably high among esophageal
squamous cell cancers at almost 70% (51). Previous work
has shown that esophageal squamous cell tumors with c-Met
overexpression demonstrate a correlation with increasing
tumor depth and pathologic stage, and is independently
associated with poorer 5-year overall survival (51).
Foretinib
Additionally, relevant to esophageal and gastric malignancies
is the finding that activation of c-Met pathways may occur
in the setting of HER2 targeted therapy. Specifically,
description of c-Met/HGF activation causing escape of
tumor cells from lapatinib-induced growth inhibition in
HER2 amplified gastric cancer cells has been reported (52).
Similarly, c-Met amplification has been associated with
resistance to EGFR therapy (erlotinib, gefitinib) in lung
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cancer patients (53). As such, potential c-Met inhibitors have
been a focus of active research. One such development has
been foretinib, an oral multikinase inhibitor (with targets
including c-Met, VEGFR, RON, and AXL), that has had
promising results in reversing the HGF induced escape
mechanisms from lapatinib and erlotinib therapy (54).
Recently, a phase II trial did not show any efficacy in overall
response rate, progression free survival, or overall survival for
foretinib alone among poorly differentiated locally advanced
or metastatic gastric adenocarcinoma patients, but has not yet
been evaluated in conjunction with HER2 targeted therapy,
or among esophageal squamous cell patients, where the
prevalence of c-Met overexpression is higher (55).
Onartuzumab
Results of a phase II trial of onartuzumab, a monoclonal
antibody with activity against c-Met in conjunction
with FOLFOX6 for advanced gastroesophageal cancer
demonstrated no difference in the primary end-point
(progression-free survival) (56). Of note, approximately 30%
of patients in each arm were c-Met positive patients (≥50% of
tumor with moderate to strong intensity staining on IHC), and
even among this enriched subgroup, no benefit was detected.
In a phase III trial with metastatic HER2 negative, c-Met
positive gastroesophageal cancer patients again comparing
first line FOLFOX6 to FOLFOX6 with onartuzumab
(METGastric), no difference in overall survival was detected
for the enrolled group or among strongly (2+, 3+) c-MET
positive patients (57). Exploratory subgroup analyses did
show improved overall survival among non-Asian patients
and in patients without gastrectomy, with any c-MET status.
Rilotumumab
In an alternative effort to interfere with the c-MET
HGF pathway, rilotumumab was developed as a human
monoclonal antibody with high affinity for HGF, thereby
preventing it from binding to the c-MET receptor. A phase
II trial examining the use of rilotumumab with epirubicin,
cisplatin, and capecitabine for first-line treatment of
locally advanced or metastatic gastroesophageal or gastric
adenocarcinoma, suggested an improvement in progression
free survival events for patients receiving rilotumumab
versus placebo (58). Based on these findings, a phase III
trial was developed (RILOMET-1), but was stopped early
secondary to increased mortality in in the rilotumumab
arm (59). Patients in the rilotumumab arm had poorer
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overall survival (9.6 vs. 11.5 months, P=0.016) and objective
response rate (30% vs. 39.2%, P=0.03). On subgroup
analysis, rilotumumab was still not associated with any
improvement in survival, even for patients with ≥1+ c-MET
expression. With these findings, the use of rilotumumab in
other clinical trials was halted as well.
Mechanistic target of rapamycin (mTOR)
targeted therapy
mTOR is a protein kinase with an impressive array of cellular
functions when activated, including cell proliferation, growth,
transcription, and protein synthesis. Pathologic comparisons
of gastric adenocarcinoma to normal gastric mucosa have
demonstrated increased expression of mTOR in tumor
samples, as well as upstream proteins known to activate
mTOR, such as PI3K and AKT (60). PTEN, a known
regulator of mTOR activation (by inhibiting the PI3K/
AKT/mTOR pathway) has been found to be significantly
lower in gastric tumor samples. Further work established the
correlation between increased cytoplasmic mTOR expression
and depth of gastric adenocarcinoma invasion, lymph node
involvement, more advanced tumor stage, poorer relapsefree survival and overall survival (61). Alternatively, nuclear
mTOR expression was negatively correlated with tumor
invasiveness and poorer survival outcomes.
Everolimus
Everolimus has long been used as an oral mTOR inhibitor
in solid organ transplant patients as an immunosuppressive
agent, but began to gather attention as a novel agent
for renal cell carcinoma, pancreatic neuroendocrine
tumors, and select breast cancer patients (ER/PR positive,
HER2 negative). A phase II study of everolimus (with
standard dosing of 10 mg daily) as a second-line agent for
patients with advanced gastric adenocarcinoma who had
demonstrated progression on prior chemotherapy showed
a promising disease control rate of 56% and median
progression-free survival of 2.7 months (62). However, a
phase III trial of everolimus in the same patient population
(GRANITE-1) approached, but did not reach significance
in median overall survival between the everolimus arm and
the placebo group (5.4 vs. 4.3 months, P=0.12) (63).
Immunotherapy targets
With breakthrough agents in the realm of immunomodulation
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therapy for melanoma, lymphoma and other malignancies,
attention has begun to shift to the possible role and efficacy
of immune checkpoint inhibitors for gastrointestinal
cancers. One approach that is currently at the forefront of
such research is blockading the interaction between T-cells
and tumor cells through programmed death-1 receptorligand binding. While this interaction inhibits T-cell
costimulation and facilitates evasion of the tumor cell from
the immune system, targeted inhibitors can block the binding
of the cytotoxic T-cell receptor to the tumor cell programmed
death-1 ligand (PDL1) (64). Anti-PD1 therapy has already
demonstrated impressive and durable improvements in
clinical responses in patients with melanoma, non-small cell
lung cancer, and renal cell carcinoma (65-67). Features that
make gastroesophageal cancers attractive for this type of
checkpoint therapy include high rates of somatic mutations
as well as the identification of gastric cancer subtypes with
high PD-L1 expression (68,69).
Pembrolizumab
Previous analysis of tumor samples from stage II and
III gastric cancer patients has demonstrated that PDL1
overexpression was observed in approximately 30% of
patients, and was independently associated with poorer
overall survival, suggesting that this may be an actionable
target for subgroups of patients with these tumors (70).
The KEYNOTE-012 phase Ib trial was a multicenter
study that evaluated pembrolizumab, a humanized antibody
against PD-1, in patients with a variety of malignancies
including advanced gastric, urothelial, head and neck, and
triple negative breast cancer (71). Patients were eligible
for entry into the gastric cancer cohort if they were
determined to have PD-L1 positive recurrent or metastatic
adenocarcinoma of the gastroesophageal junction or stomach
(after any therapy type, but excluding previous treatment
with other immune checkpoint inhibitors), and were given
pembrolizumab every 2 weeks for 24 months or until disease
progression, death, toxicity, or study withdrawal. PDL1
positivity was initially assessed by membrane staining in at
least 1% of cells in a section of archived tumor cells and then
re-evaluated with a prototype immunohistochemistry assay
that assigned PDL1 density scores to both the tumor cells as
well as mononuclear inflammatory cells. Of the 162 patients
screened, 40% demonstrated PD-L1 positivity (72).
Of the 36 patients in the gastric malignancy cohort of
the KEYNOTE-012 trial that were able to be evaluated,
22% (95% CI, 10–39%) demonstrated partial response
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to pembrolizumab with a median duration of response of
40 weeks, with 4 patients continuing to have no evidence
of disease progression. No patients in the study achieved
a complete response rate. This response rate was similar
between Asian institutions and other geographic centers.
Of note, patients with a higher mononuclear inflammatory
PDL1 cell density score experienced a higher partial
response rate (score 3: 44%) than patients with a high tumor
PDL1 proportion (50–100%: 33%). No treatment-related
treatment discontinuation or deaths occurred, and only
13% of patients experienced grade 3 (fatigue, pemphigoid,
hypothyroidism, peripheral neuropathy) or 4 (pneumonitis)
complications. Median overall survival was 11.4 months
(95% CI, 5.7–not reached). Interestingly, 8 patient biopsies
assessed at the time of data completion had essentially
negative PDL1 status (mononuclear inflammatory PDL1
cell density score of 1 or less and tumor PDL1 proportion
of 0), possibly suggesting changes in PDL1 expression
following treatment with pembrolizumab or heterogeneity
of the gastric tumors (73).
Recently, pembrolizumab was also evaluated in esophageal
cancer (squamous cell or adenocarcinoma histology) as a
phase Ib trial in patients with a similar PD-L1 positivity and
treatment regimen as described in KEYNOTE-012 (74).
In this trial, 41% of enrolled esophageal cancer patients
demonstrated PD-L1 positivity, with a patient population
that skewed to squamous cell (77%). Of note, the majority
(87%) of patients had received two or more previous types of
systemic therapy prior to participation in the study. Objective
response rate in this trial was 23%, with no drug related
adverse events greater than grade 3. Currently, the phase II
KEYNOTE-180 study is also evaluating pembrolizumab
in advanced or metastatic esophageal adenocarcinoma or
squamous cell cancer that has progressed on two prior
agents (including trastuzumab if HER2 positive) (75).
Nivolumab
Nivolumab, another human monoclonal antibody targeted
against PD-1 with efficacy demonstrated in various
malignancies including melanoma and non-small cell lung
cancer has also been considered for upper gastrointestinal
tumors. Reports from a phase I/II trial (part of the
CheckMate-032 study) with 59 advanced or metastatic
gastroesophageal or gastric cancer patients treated
with single agent nivolumab demonstrated an objective
response rate of 12%, with one complete response and
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6 partial responses (76). Of note, 39% of tumor samples
were classified as PD-L1 positive, with a higher objective
response rate (18%). About 21% of patients were noted to
have stable disease. Given these findings, it is feasible that
nivolumab may be considered for further evaluation in a
randomized controlled trial.
Conclusions and future directions
While advanced esophageal, esophagogastric, and gastric
malignancies continue to have a prominent global presence
with poor 5-year survival outcomes, significant gains
are starting to be made with the use of targeted biologic
therapies. In the near future, the evaluation and clinical use
of these agents will be greatly assisted by comprehensive
characterizations and subclassifications of gastric and
related GI malignancies. This massive effort is already
underway in projects such as The Cancer Genome Atlas
Research Network (TCGA) which is working to organize
gastric malignancies into four subtypes each with a distinct
and relatively predictable mutation profiles: Ebstein-Barr
positive tumors, genomically stable tumors, tumors with
microsatellite instability, and tumors with chromosomal
instability (77).
While not all agents (EGFR inhibitors) have demonstrated
the same efficacy in esophageal and gastric malignancies
that they have accomplished for other tumor types, others
are now employed as recommended agents in progressive or
refractory disease (trastuzumab and ramucirumab). Others,
such as lapatinib, onartuzumab, and bevacizumab, may
demonstrate improved efficacy among specific geographic
populations and warrant further tailored investigation.
Furthermore, the potential agents for immunomodulation
therapy continue to expand and pose exciting developments
for esophageal and gastric malignancies. While the pace
of biologic therapies, including immunotherapy agents, in
phase I, II, and III trials continue at a fervent pace, important
components to contextualize these studies will include the
role of potential biomarkers to guide tailored therapy, as
well as decision and cost-effectiveness analyses to assist in
determining which agents will impart the most substantial
and meaningful benefits.
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